自動注射器の世界市場2020–2027:種類別(使い捨て自動注射器、再利用可能自動注射器)、用途別、エンドユーザー別

◆英語タイトル:Autoinjectors Market by Type (Disposable Autoinjectors and Reusable Autoinjectors), Application (Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, and Others), and End user (Homecare Settings and Hospitals & Clinics): Global Opportunity Analysis and Industry Forecast, 2020–2027
◆商品コード:ALD20NV09
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2020年9月
◆ページ数:225
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,769 ⇒換算¥599,976見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥670,800見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥935,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、自動注射器の世界市場を調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、種類別(使い捨て自動注射器、再利用可能自動注射器)分析、用途別(関節リウマチ、多発性硬化症、アナフィラキシー、その他)分析、エンドユーザー別(在宅医療、病院・クリニック)分析、企業情報、地域別と今後の方向性を明らかに致します。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・自動注射器の世界市場規模:種類別(使い捨て自動注射器、再利用可能自動注射器)
・自動注射器の世界市場規模:用途別(関節リウマチ、多発性硬化症、アナフィラキシー、その他)
・自動注射器の世界市場規模:エンドユーザー別(在宅医療、病院・クリニック)
・自動注射器の世界市場規模:地域別
・企業情報
【レポートの概要】

The global autoinjectors market was valued at $ 1,509.0 million in 2019 and is expected to reach $ 5,732.6 million by 2027, with a CAGR of 18.1% during the forecast period.
An autoinjector is defined as a syringe with a spring-charged needle having a pre-charged dosage of drugs. The system triggers and administers a measured dosage of a drug when pressed into the body with a slicing motion. Autoinjectors are widely used for epinephrine self-administration (to prevent anaphylaxis); by migraine sufferers (for immediate pain relief); or for medical and emergency treatments. Auto-injectors provide multiple benefits such as decreasing needle-related phobia disorder, decreasing risks of needle stuck accidents, ensuring dosage quality continuity, and helping to increase effectiveness.

The autoinjector market is expected to register a substantial growth in the future, owing to rise in anaphylaxis cases. In addition, increase in R&D efforts by companies to develop simple, cost effective, and new technology based autoinjectors for treatment of chronic diseases such as rheumatoid arthritis and multiple sclerosis is expected to boost the market growth during the forecast period.
However, availability of alternative treatment options is anticipated to hamper the market growth during the forecast period. On the contrary, a fundamental shift from biologics to biosimilars , which are delivered through autoinjectors are anticipated to provide lower cost options to patients opting for prolonged treatment. These factors are expected to provide remunerative opportunities for the market players.
Depending on type, the market is categorized into disposable and reusable autoinjectors. The disposable autoinjectors segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. The key factors such as rise in prevalence of anaphylaxis and rheumatoid arthritis and further increasing patient preference for autoinjectors drives the growth of this treatment segment.
On the basis of application, the market is categorized into rheumatoid arthritis, multiple sclerosis, anaphylaxis, and others. The anaphylaxis segment held a dominant position in the market, accounting for about 38.5% share of the global autoinjectors market in 2019.
By end user, the market is categorized into home care settings and hospitals & clinics. The home care settings segment held a dominant portion in the market, accounting for about 62.8% share of the global autoinjectors market in 2019.
North America accounted for the largest share in the global autoinjectors market. Asia-Pacific is expected to witness highest growth rate for throughout the forecast period. Rise in cases of anaphylaxis; rheumatoid arthritis; and other diseases such as anemia and migraine; and further increase in technological advancements by companies are anticipated to drive the overall market growth.

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current autoinjectors trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
• The market forecast is studied from 2020 to 2027.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS
By Type
• Disposable autoinjectors
• Reusable autoinjectors

By Application
• Rheumatoid Arthritis
• Anaphylaxis
• Multiple Sclerosis
• Others

By End user
• Home care settings
• Hospitals & Clinics

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA

KEY MARKET PLAYERS
• Amgen
• Antares Pharma
• Becton Dickinson and Company
• Eli Lilly and Company
• Johnson and Johnson
• Mylan N.V.
• Novartis AG
• SHL Medical
• Teva Pharmaceutical Industries Ltd
• Ypsomed AG

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top winning strategies
3.2.2.Top player positioning
3.2.3.Key forces shaping the global autoinjectors market

3.3.Market dynamics

3.3.1.Drivers

3.3.1.1.Rise in anaphylaxis
3.3.1.2.Patients preference to choose self-administration of injections
3.3.1.3.Technological advancements in autoinjectors

3.3.2.Restraint

3.3.2.1.Availability of alternative treatment options such as general injections and oral tablets

3.3.3.Opportunities

3.3.3.1.Patent expiry of biologics to fuel biosimilar demands

CHAPTER 4:AUTOINJECTORS MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Disposable autoinjectors

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Reusable autoinjectors

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

CHAPTER 5:AUTOINJECTORS MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Rheumatoid arthritis

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Multiple Sclerosis

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Anaphylaxis

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Others

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

CHAPTER 6:AUTOINJECTORS MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Home care settings

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Hospitals & Clinics

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

CHAPTER 7:GLOBAL AUTOINJECTORS MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by type
7.2.3.Market size and forecast, by application
7.2.4.Market size and forecast, by end user
7.2.5.Market size and forecast, by country

7.2.5.1.U.S.

7.2.5.1.1.U.S. market size and forecast, by type
7.2.5.1.2.U.S. market size and forecast, by application
7.2.5.1.3.U.S. market size and forecast, by end user9

7.2.5.2.Canada

7.2.5.2.1.Canada market size and forecast, by type
7.2.5.2.2.Canada market size and forecast, by application
7.2.5.2.3.Canada market size and forecast, by end user

7.2.5.3.Mexico

7.2.5.3.1.Mexico market size and forecast, by type
7.2.5.3.2.Mexico market size and forecast, by application
7.2.5.3.3.Mexico market size and forecast, by end user

7.3.Europe

7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by type
7.3.3.Market size and forecast, by application
7.3.4.Market size and forecast, by end user
7.3.5.Market size and forecast, by country

7.3.5.1.Germany

7.3.5.1.1.Germany market size and forecast, by type
7.3.5.1.2.Germany market size and forecast, by application
7.3.5.1.3.Germany market size and forecast, by end user

7.3.5.2.France

7.3.5.2.1.France market size and forecast, by type
7.3.5.2.2.France market size and forecast, by application
7.3.5.2.3.France market size and forecast, by end user

7.3.5.3.UK

7.3.5.3.1.UK market size and forecast, by type
7.3.5.3.2.UK market size and forecast, by application
7.3.5.3.3.UK market size and forecast, by end user

7.3.5.4.Italy

7.3.5.4.1.Italy market size and forecast, by type
7.3.5.4.2.Italy market size and forecast, by application
7.3.5.4.3.Italy market size and forecast, by end user

7.3.5.5.Spain

7.3.5.5.1.Spain market size and forecast, by type
7.3.5.5.2.Spain market size and forecast, by application
7.3.5.5.3.Spain market size and forecast, by end user

7.3.5.6.Rest of Europe

7.3.5.6.1.Rest of Europe market size and forecast, by type
7.3.5.6.2.Rest of Europe market size and forecast, by application
7.3.5.6.3.Rest of Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by type
7.4.3.Market size and forecast, by application
7.4.4.Market size and forecast, by end user
7.4.5.Market size and forecast, by country

7.4.5.1.Japan

7.4.5.1.1.Japan market size and forecast, by type
7.4.5.1.2.Japan market size and forecast, by application
7.4.5.1.3.Japan market size and forecast, by end user

7.4.5.2.China

7.4.5.2.1.China market size and forecast, by type
7.4.5.2.2.China market size and forecast, by application
7.4.5.2.3.China market size and forecast, by end user

7.4.5.3.India

7.4.5.3.1.India market size and forecast, by type
7.4.5.3.2.India market size and forecast, by application
7.4.5.3.3.India market size and forecast, by end user

7.4.5.4.Australia

7.4.5.4.1.Australia market size and forecast, by type
7.4.5.4.2.Australia market size and forecast, by application
7.4.5.4.3.Australia market size and forecast, by end user

7.4.5.5.Rest of Asia-Pacific

7.4.5.5.1.Rest of Asia-Pacific market size and forecast, by type
7.4.5.5.2.Rest of Asia-Pacific market size and forecast, by application
7.4.5.5.3.Rest of Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by type
7.5.3.Market size and forecast, by application
7.5.4.Market size and forecast, by end user
7.5.5.Market size and forecast, by country160

7.5.5.1.Brazil

7.5.5.1.1.Brazil market size and forecast, by type
7.5.5.1.2.Brazil market size and forecast, by application
7.5.5.1.3.Brazil market size and forecast, by end user

7.5.5.2.Saudi Arabia

7.5.5.2.1.Saudi Arabia market size and forecast, by type
7.5.5.2.2.Saudi Arabia market size and forecast, by application
7.5.5.2.3.Saudi Arabia market size and forecast, by end user

7.5.5.3.South Africa

7.5.5.3.1.South Africa market size and forecast, by type
7.5.5.3.2.South Africa market size and forecast, by application
7.5.5.3.3.South Africa market size and forecast, by end user

7.5.5.4.Rest of LAMEA

7.5.5.4.1.Rest of LAMEA market size and forecast, by type
7.5.5.4.2.Rest of LAMEA market size and forecast, by application
7.5.5.4.3.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.AMGEN INC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.ANTARES PHARMA

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.BECTON, DICKINSON, AND COMPANY (BD)

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.ELI LILLY AND COMPANY

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.JOHNSON & JOHNSON

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.MYLAN N.V.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.NOVARTIS AG

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.SHL MEDICAL AG

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Product portfolio
8.8.4.Key strategic moves and developments

8.9.TEVA PHARMACEUTICAL INDUSTRIES LTD.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.YPSOMED AG

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.AUTOINJECTORS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 02.AUTOINJECTORS MARKET FOR DISPOSABLE AUTOINJECTORS, BY REGION, 2019–2027($MILLION)
TABLE 03.AUTOINJECTORS MARKET FOR REUSABLE AUTOINJECTORS, BY REGION, 2019–2027($MILLION)
TABLE 04.AUTOINJCETORS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 05.AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2019–2027($MILLION)
TABLE 06.AUTOINJECTORS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2019–2027($MILLION)
TABLE 07.AUTOINJECTORS MARKET FOR ANAPHYLAXIS, BY REGION, 2019–2027($MILLION)
TABLE 08.AUTOINJECTORS MARKET FOR OTHERS, BY REGION, 2019–2027($MILLION)
TABLE 09.AUTOINJECTORS MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 10.AUTOINJECTORS MARKET FOR HOME CARE SETTINGS , BY REGION, 2019–2027($MILLION)
TABLE 11.AUTOINJECTORS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2019–2027($MILLION)
TABLE 12.AUTOINJECTORS MARKET, BY REGION 2019–2027, ($MILLION)
TABLE 13.NORTH AMERICA AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 14.NORTH AMERICA AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 15.NORTH AMERICA AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 16.NORTH AMERICA AUTOINJECTORS MARKET, BY COUNTRY, 2019–2027, ($MILLION)
TABLE 17.U.S. AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 18.U.S. AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 19.U.S. AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 20.CANADA AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 21.CANADA AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 22.CANADA AUTOINJECTORS MARKET, BY END USER , 2019–2027, ($MILLION)
TABLE 23.MEXICO AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 24.MEXICO AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 25.MEXICO AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 26.EUROPE AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 27.EUROPE AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 28.EUROPE AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 29.EUROPE AUTOINJECTORS MARKET, BY COUNTRY, 2019–2027, ($MILLION)
TABLE 30.GERMANY AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 31.GERMANY AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 32.GERMANY AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 33.FRANCE AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 34.FRANCE AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 35.FRANCE AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 36.UK AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 37.UK AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 38.UK AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 39.ITALY AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 40.ITALY AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 41.ITALY AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 42.SPAIN AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 43.SPAIN AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 44.SPAIN AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 45.REST OF EUROPE AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 46.REST OF EUROPE AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 47.REST OF EUROPE AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 48.ASIA-PACIFIC AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 49.ASIA-PACIFIC AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 50.ASIA-PACIFIC AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 51.ASIA-PACIFIC AUTOINJECTORS MARKET, BY COUNTRY, 2019–2027, ($MILLION)
TABLE 52.JAPAN AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 53.JAPAN AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 54.JAPAN AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 55.CHINA AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 56.CHINA AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 57.CHINA AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 58.INDIA AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 59.INDIA AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 60.INDIA AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 61.AUSTRALIA AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 62.AUSTRALIA AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 63.AUSTRALIA AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 64.REST OF ASIA-PACIFIC AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 65.REST OF ASIA-PACIFIC AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 67.LAMEA AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 68.LAMEA AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 69.LAMEA AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 70.LAMEA AUTOINJECTORS MARKET, BY COUNTRY, 2019–2027, ($MILLION)
TABLE 71.BRAZIL AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 72.BRAZIL AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 73.BRAZIL AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 74.SAUDI ARABIA AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 75.SAUDI ARABIA AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 76.SAUDI ARABIA AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 77.SOUTH AFRICA AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 78.SOUTH AFRICA AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 79.SOUTH AFRICA AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 80.REST OF LAMEA AUTOINJECTORS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 81.REST OF LAMEA AUTOINJECTORS MARKET, BY APPLICATION, 2019–2027, ($MILLION)
TABLE 82.REST OF LAMEA AUTOINJECTORS MARKET, BY END USER, 2019–2027, ($MILLION)
TABLE 83.AMGEN: COMPANY SNAPSHOT
TABLE 84.AMGEN: OPERATING SEGMENTS
TABLE 85.AMGEN: PRODUCT PORTFOLIO
TABLE 86.AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 87.ANTARES : COMPANY SNAPSHOT
TABLE 88.ANTARES: OPERATING SEGMENTS
TABLE 89.ANTARES: PRODUCT PORTFOLIO
TABLE 90.ANTARES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 91.BD: COMPANY SNAPSHOT
TABLE 92.BD: OPERATING SEGMENTS
TABLE 93.BD: PRODUCT PORTFOLIO
TABLE 94.BD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 95.LILLY: COMPANY SNAPSHOT
TABLE 96.LILLY: OPERATING SEGMENTS
TABLE 97.LILLY: PRODUCT PORTFOLIO
TABLE 98.JOHNSON AND JOHNSON : COMPANY SNAPSHOT
TABLE 99.JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 100.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 101.JOHNSON & JOHNSON: NET SALES, 2017–2019 ($MILLION)
TABLE 102.JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2019 (%)
TABLE 103.JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2019 (%)
TABLE 104.MYLAN: COMPANY SNAPSHOT
TABLE 105.MYLAN: OPERATING SEGMENTS
TABLE 106.MYLAN: PRODUCT PORTFOLIO
TABLE 107.NOVARTIS: COMPANY SNAPSHOT
TABLE 108.NOVARTIS: OPERATING SEGMENTS
TABLE 109.NOVARTIS: PRODUCT PORTFOLIO
TABLE 110.SHL : COMPANY SNAPSHOT
TABLE 111.SHL : PRODUCT PORTFOLIO
TABLE 112.SHL : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113.TEVA: COMPANY SNAPSHOT
TABLE 114.TEVA: OPERATING SEGMENTS
TABLE 115.TEVA: PRODUCT PORTFOLIO
TABLE 116.YPSOMED : COMPANY SNAPSHOT
TABLE 117.YPSOMED : OPERATING SEGMENTS
TABLE 118.YPSOMED : PRODUCT PORTFOLIO
TABLE 119.YPSOMED : KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.SEGMENTATION OF AUTOINJECTORS MARKET
FIGURE 02.TOP WINNING STRATEGIES, BY YEAR, 2017–2020
FIGURE 03.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2020 (%)
FIGURE 04.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020
FIGURE 05.TOP PLAYER POSITIONING, 2019
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTION
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITVE RIVARLY
FIGURE 11.GLOBAL AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF AUTOINJECTORS MARKET FOR DISPOSABLE AUTOINJECTORS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF AUTOINJECTORS MARKET FOR REUSABLE AUTOINJECTORS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF AUTOINJECTORS MARKET FOR MUTIPLE SCLEROSIS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF AUTOINJECTOR MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF AUTOINJECTOR MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF AUTOINJECTORS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.U.S. AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 21.CANADA AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 22.MEXICO AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 23.GERMANY AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 24.FRANCE AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 25.UK AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 26.ITALY AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 27.SPAIN AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 28.REST OF EUROPE AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 29.JAPAN AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 30.CHINA AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 31.INDIA AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 32.AUSTRALIA AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 33.REST OF ASIA-PACIFIC AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 34.BRAZIL AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 35.SAUDI ARABIA AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 36.SOUTH AFRICA AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 37.REST OF LAMEA AUTOINJECTORS MARKET, 2020–2027 ($MILLION)
FIGURE 38.AMGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.AMGEN: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 40.ANTARES: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.ANTARES: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42.ANTARES: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 43.BD: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.BD: REVENUE SHARE, BY SEGMENT (%)
FIGURE 45.BD : REVENUE SHARE BY REGION, 2019 (%)
FIGURE 46.LILLY REVENUE, 2017-2019 ($MILLION)
FIGURE 47.LILLY: REVENUE SHARE, BY THERAPEUTICS, 2019 (%)
FIGURE 48.LILLY: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 49.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 50.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 51.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 52.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 53.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 54..TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 55.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 56.YPSOMED : NET SALES, 2017–2019 ($MILLION)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[自動注射器の世界市場2020–2027:種類別(使い捨て自動注射器、再利用可能自動注射器)、用途別、エンドユーザー別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆